Items tagged with Diagnostics
India: GeneXpert is now available free of cost for pediatric TB patients in Delhi, Chennai, Hyderabad and Kolkata (post)
Any pediatrician both in public and private sector in Delhi, Chennai, Hyderabad and Kolkata can send pediatric (pulmonary and extrapulmonary) samples to one of the laboratories listed below, and get a GeneXpert TB test done free of cost. The specimen will be tested on the same day and the results communicated to the referring provider electronically (e-mail and SMS) and at the same time notified to the Revised National Tuberculosis Programme (RNTCP) under Nikshay.
NIH earmarks $2 million for pediatric TB biomarker research (post)
The National Institutes of Health announced that it aims to award $2 million in grant funding in fiscal year 2017 for research around new biomarkers to diagnose active pulmonary tuberculosis (TB) in children, including those infected with HIV.
FIND and Cepheid announce a strategic collaboration to advance point-of-care TB diagnosis (post)
CAPE TOWN, South Africa and GENEVA and SUNNYVALE, Calif., Dec. 3, 2015 -- FIND and Cepheid today announced that they are broadening their collaboration on bringing point-of-care tuberculosis (TB) diagnosis to all levels of the health system in low and middle-income countries (LMICs). The work under the collaboration will focus on evaluating and implementing Cepheid's new GeneXpert® Omni system and Xpert® MTB/RIF Ultra test, in addition to assessing the system's cloud-based connectivity. These efforts will ultimately benefit all stakeholders, as the resulting data and know-how will be made publicly available.
Scientists use breakthrough DNA technology to diagnose cases of TB faster (post)
Whole Genome Sequencing is a faster, cheaper and more effective way of diagnosing tuberculosis says a new study published in the journal Lancet Respiratory Medicine.
Dr Louise Pankhurst of the University of Oxford and a team of worldwide collaborators including Public Health England utilised innovative DNA technology to diagnose cases of tuberculosis (TB) up to eight times faster than traditional methods.
Performance of the interferon gamma release assays in tuberculosis disease in children five years old or less (post)
Abstract
Devising an inexpensive, quick tuberculosis test for developing areas (post)
Tuberculosis (TB) is a highly infectious disease and a major global health problem, especially in countries with developing health care systems. Because there is no fast, easy way to detect TB, the deadly infection can spread quickly through communities. Now, a team reports in ACS Sensors the development of a rapid, sensitive and low-cost method for detecting the disease in resource-limited areas.
Avisa’s biomarker breath test detects tuberculosis in South Africa pilot study (post)
SANTA FE, N.M., December 18, 2015 -- Avisa Pharma Inc. announced today that it successfully detected active TB in a pilot study in Durban, South Africa. The study had three cohorts, suspected TB subjects who were HIV negative, suspected TB subjects who were HIV positive and controls. The AV-BreathTest™ detected TB in both HIV+ and HIV- cohorts confirmed by PCR and standard TB culture. The AV-BreathTest™ measures the whole lung, in vivo, does not require sputum, and is point-of-care. The time from test initiation to result is less than 10 minutes, and the breath test has the potential to monitor antibiotic therapy. There are 9.5 million active TB cases worldwide, of which 1 million are children who have difficulty producing sputum and require traditional tests with more invasive procedures.
International consensus statement on molecular diagnosis of tuberculosis drug-resistance released (post)
Multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are challenging tuberculosis control globally. Early identification of patients with MDR-TB and XDR-TB and the complex pattern of Mycobacterium tuberculosis drug resistance are key to providing each individual patient with the correct therapy. Traditionally, identification of the spectrum of bacillary drug resistance takes several weeks to a few months, leading to under-treatment or incorrect treatment in many cases.
Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in 19 low- and middle-income countries (post)
Three quarters of people with HIV/TB co-infection did not receive Xpert MTB/RIF testing for TB diagnosis between 2012 and 2014, according to a survey of cohorts in 19 low- and middle-income countries by the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, presented by Dr Kate Clouse at the 46th Union World Conference on Lung Health in Cape Town from 2 to 6 December.
LAM point-of-care TB testing reduces mortality in people with HIV/TB co-infection in hospital (post)
All-cause 8-week mortality is reduced by rapid point-of-care urine-based testing for tuberculosis (TB), using a test for detection of mycobacterial lipoarabinomannan (LAM) to guide rapid treatment initiation in hospitalised HIV-positive people with signs and symptoms of TB, according to a late-breaker study presented by Dr Jonny Peter of the University of Cape Town, and colleagues, at the 46th Union World Conference on Lung Health in Cape Town from 2 to 6 December 2015.
Page 12 of 70 · Total posts: 0
←First 11 12 13 Last→